Article: Mycophenolate mofetil for autoimmune cytopenias in children: high rates of response in inborn errors of immunity.
2023 Volume 11, Page(s) 1174671
Abstract: Second-line treatments of autoimmune cytopenias (AC) are not well-defined in children. Mycophenolate mofetil (MMF) is an immunosuppressant agent that has been demonstrated to be safe and effective in this setting. A retrospective observational study was ... ...
Abstract | Second-line treatments of autoimmune cytopenias (AC) are not well-defined in children. Mycophenolate mofetil (MMF) is an immunosuppressant agent that has been demonstrated to be safe and effective in this setting. A retrospective observational study was conducted in 18 children with prolonged AC who received MMF, in order to describe clinical and biological markers of response. The overall response rate of MMF at 20-30 mg/kg per day was 73.3%. All patients with Evans syndrome ( |
---|---|
Language | English |
Publishing date | 2023-10-17 |
Publishing country | Switzerland |
Document type | Journal Article |
ZDB-ID | 2711999-3 |
ISSN | 2296-2360 |
ISSN | 2296-2360 |
DOI | 10.3389/fped.2023.1174671 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.